# Entecavir Prophylaxis for Hepatitis B Reactivation for CD20 Positive B-cell Lymphoma Patients With Resolved Hepatitis B (Negative Hepatitis B Surface Antigen, Positive Hepatitis B Core Antibody)

> **NCT05453435** · PHASE2 · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 84 (estimated)

## Conditions studied

- Resolved Hepatitis B
- CD20 Positive B-cell Lymphoma

## Interventions

- **DRUG:** Entecavir

## Key facts

- **NCT ID:** NCT05453435
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-07-15
- **Primary completion:** 2025-07
- **Final completion:** 2025-07
- **Target enrollment:** 84 (ESTIMATED)
- **Last updated:** 2024-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05453435

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05453435, "Entecavir Prophylaxis for Hepatitis B Reactivation for CD20 Positive B-cell Lymphoma Patients With Resolved Hepatitis B (Negative Hepatitis B Surface Antigen, Positive Hepatitis B Core Antibody)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05453435. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*